Phreesia (NYSE:PHR) Stock Rating Reaffirmed by Royal Bank of Canada

Royal Bank of Canada reissued their sector perform rating on shares of Phreesia (NYSE:PHR) in a research note issued to investors on Thursday morning, Benzinga reports. Royal Bank of Canada currently has a $23.00 target price on the stock.

A number of other analysts also recently weighed in on PHR. Stephens reissued an overweight rating and issued a $28.00 price target on shares of Phreesia in a report on Friday, May 31st. DA Davidson reissued a buy rating and set a $32.00 target price on shares of Phreesia in a research report on Thursday. KeyCorp lowered their price target on Phreesia from $27.00 to $25.00 and set an overweight rating on the stock in a research note on Thursday, July 11th. Truist Financial reiterated a buy rating and issued a $29.00 price objective on shares of Phreesia in a research report on Monday, July 1st. Finally, JMP Securities restated a market outperform rating and set a $30.00 price objective on shares of Phreesia in a research report on Friday, August 30th. One analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of Moderate Buy and an average price target of $30.42.

Phreesia Stock Down 8.3 %

Shares of PHR stock opened at $23.55 on Thursday. The stock has a 50 day moving average of $23.38 and a 200-day moving average of $22.77. The firm has a market cap of $1.35 billion, a PE ratio of -10.85 and a beta of 0.93. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.03. Phreesia has a 12 month low of $12.05 and a 12 month high of $29.16.

Insider Buying and Selling at Phreesia

In other news, CEO Chaim Indig sold 2,644 shares of the company’s stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $23.74, for a total value of $62,768.56. Following the sale, the chief executive officer now owns 1,219,361 shares of the company’s stock, valued at approximately $28,947,630.14. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Phreesia news, CEO Chaim Indig sold 2,644 shares of the business’s stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $23.74, for a total value of $62,768.56. Following the transaction, the chief executive officer now directly owns 1,219,361 shares in the company, valued at $28,947,630.14. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Mark Douglas Smith sold 7,000 shares of the company’s stock in a transaction dated Thursday, July 18th. The stock was sold at an average price of $25.00, for a total transaction of $175,000.00. Following the sale, the director now directly owns 30,653 shares in the company, valued at $766,325. The disclosure for this sale can be found here. Over the last three months, insiders sold 29,337 shares of company stock valued at $736,750. 5.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Phreesia

Several institutional investors have recently bought and sold shares of the business. New York State Common Retirement Fund raised its holdings in shares of Phreesia by 13.0% in the fourth quarter. New York State Common Retirement Fund now owns 53,865 shares of the company’s stock valued at $1,247,000 after buying an additional 6,200 shares during the last quarter. Russell Investments Group Ltd. raised its stake in shares of Phreesia by 5,462.3% in the fourth quarter. Russell Investments Group Ltd. now owns 3,838 shares of the company’s stock worth $89,000 after acquiring an additional 3,769 shares during the last quarter. Los Angeles Capital Management LLC acquired a new position in shares of Phreesia during the fourth quarter worth approximately $242,000. M&T Bank Corp bought a new stake in shares of Phreesia during the fourth quarter valued at approximately $527,000. Finally, Private Advisor Group LLC acquired a new stake in shares of Phreesia in the fourth quarter valued at approximately $263,000. Institutional investors own 92.10% of the company’s stock.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.